血栓形成是由于血小板活化和凝血系统激活引起的血液凝固，一直是临床治疗的难题。富含亮氨酸重复序列相互作用蛋白1（Leucinerich repeatinteracting protein 1, LRRFIPl）是凝溶胶蛋白家族成员之一，在损伤的颈动脉壁平滑肌细胞和中脑动脉闭塞后的皮质和纹状体中均异常表达，并能抑制多个与凝血相关基因的表达，是血小板细胞骨架的组成部分，提示其可能参与血栓的形成。本课题拟采用LRRFIPl重组突变型蛋白，抗LRRFIPl单克隆抗体等多种研究手段，从血小板生理功能、体内血栓形成模型和生理性止血三个层面，研究LRRFIPl基因在血栓形成和止血过程中的特异性作用，并探讨其分子机制，为探寻深静脉血栓新的治疗方法提供理想的靶分子。

Thrombosis is induced by platelet activation and blood coagulation system activation, which has been a clinical problem. Leucinerich repeatinteracting protein 1 (LRRFIPl) is one of gelsolin family members, which is abnormal expression in both the injured carotid artery smooth muscle cells and the cerebral cortex and striatum after arterial occlusion, and can inhibit the expression of multiple genes associated with coagulation, is part of the cytoskeleton of platelets, suggesting that it may be involved in thrombosis. In this study, we will use a variety of research methods including LRRFIPl mutant recombinant proteins, anti-LRRFIPl monoclonal antibodies, in three physiological level including physiological function of platelets, thrombosis model in vivo and physiological hemostasis, to investigate the key role of LRRFIPl in process of.thrombosis and hemostasis, and to explore the molecular mechanisms, which provides a target molecule to explore new treatments of deep vein thrombosis.